Enveric Biosciences Adds Another Data Point to Its Case That EB-003 Won’t Get You High

Enveric Biosciences is trying to answer one of the trickiest questions in the psychedelic drug space: can you get the antidepressant benefits people associate with psychedelics without the trip? On August 5, 2026, the Cambridge, Massachusetts-based biotech (NASDAQ: ENVB) released new preclinical data it says strengthens the argument that its lead candidate, EB-003, can do exactly that.

The company ran EB-003 through a Promega GloSensor™ cAMP assay — a live-cell test built to pick up on subtle Gi-coupled receptor activity, the kind of signaling that’s proven hard to measure precisely in the past. Enveric put EB-003 through the assay side by side with reference compounds already known to be hallucinogenic or non-hallucinogenic, essentially using them as a yardstick.

The result: EB-003 landed in the same range as the non-hallucinogenic comparators.

That matters because of a piece of context Enveric leaned on heavily in its release — a 2026 Nature paper from Xu and colleagues that tied hallucinogenic effects to a specific signaling pathway downstream of the 5-HT2A serotonin receptor, known as Gi-mediated signaling. The stronger a compound activates that Gi pathway, the paper suggests, the more likely it is to produce hallucinations in humans. If that holds up, it gives drug developers something they haven’t really had before: a preclinical signal that might predict whether a compound will be a “trip” before it ever reaches a human trial.

This isn’t Enveric’s first swing at making this case. Back in February 2026, the company published data from its own proprietary BRET (bioluminescence resonance energy transfer) assays showing that EB-003 engages two other signaling pathways at the 5-HT2A receptor — Gq and β-arrestin — with a slight lean toward β-arrestin relative to serotonin itself. Those pathways have been linked in other peer-reviewed research to antidepressant- and anxiolytic-like effects, independent of hallucination.

Line the two studies up and the story Enveric is telling gets clearer: EB-003 appears to light up the pathways associated with therapeutic benefit (Gq and β-arrestin) while staying quiet on the pathway increasingly associated with hallucinations (Gi). Two different assay methods, tested at two different points, pointing in the same direction — that consistency is the real headline here, more than either data set on its own.

EB-003 itself is designed to hit both 5-HT2A and 5-HT1B receptors, and Enveric describes it as the first candidate built specifically to engage both. The goal is a fast-acting, durable antidepressant and anti-anxiety effect that could be delivered in a normal outpatient setting — no dissociative episode, no need for a clinician to sit with the patient through hours of altered consciousness.

The regulatory backdrop is arguably as important as the receptor biology. The FDA has recently issued final guidance addressing the specific headaches that come with developing hallucinogenic psychedelic therapies — things like functional unblinding (patients and raters can often tell who got the real drug versus placebo, which undermines a trial’s integrity), the need for extended monitoring, and mandatory psychotherapy components built into treatment.

Enveric’s bet is that if EB-003’s non-hallucinogenic profile holds up in humans, it could sidestep a lot of that complexity: more conventional blinded trials, a simpler outpatient dosing model, and, down the line, an easier path to broader commercial adoption than hallucinogenic competitors face.

CEO Joseph Tucker framed it plainly in the release, saying the consistency across multiple independent assay platforms validates the company’s approach heading into Phase 1, and that a non-hallucinogenic option could offer real advantages in both clinical development and patient access.

For a company operating in a field where “does the patient have to hallucinate for this to work” is one of the central open questions, two independent assay platforms pointing the same way is a meaningfully stronger position than one alone. The next real test comes when EB-003 moves into humans — that’s when Enveric will find out if its receptor-level biology translates into the outpatient-friendly, non-hallucinogenic therapy it’s designed to be.